One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage All Access membership.
Explore Editage All Accesshttps://doi.org/10.1200/jco.2014.32.15_suppl.8112
Copy DOI Journal: Journal of Clinical Oncology |  Publication Date: May 20, 2014 |
 Citations: 43 |
Affiliation: Sidney Kimmel Comprehensive Cancer Center, Bristol-Myers Squibb (United States), Yale Cancer Center, Memorial Sloan Kettering Cancer Center, Christ Hospital, Carolina BioOncology Institute, Vanderbilt University Medical Center, Massachusetts General Hospital, Dana-Farber Cancer Institute, Tennessee Oncology, Sarah Cannon, University of Michigan–Ann Arbor, Moffitt Cancer Center8112^ Background: Nivolumab, a fully human IgG4, PD-1 immune-checkpoint inhibitor antibody, has shown durable clinical activity in a large phase I trial of pts with advanced solid tumors. For NSCLC...
Sign-in/Register to access full text options 
Free) Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
